Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,089 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04422210 | A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC). | terminated | Phase 1 | 2 | Hoffmann-La RocheINDUSTRY | 4 | Nov 8, 2021 | clinicaltrials |
| NCT02128282 | Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma | completed | Phase 1 / Phase 2 | 127 | Senhwa Biosciences, Inc.INDUSTRY | 3 |
| Oct 22, 2021 |
| clinicaltrials |
| NCT04882163 | Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | CelgeneINDUSTRY | 8 | Oct 5, 2021 | clinicaltrials |
| NCT04453241 | Immunogenicity and Safety Study of NBP615 in Healthy Female | completed | Phase 1 / Phase 2 | 200 | SK Bioscience Co., Ltd.INDUSTRY | 1 | Oct 1, 2021 | clinicaltrials |
| NCT02305563 | An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 70 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 16, 2021 | clinicaltrials |
| NCT04014257 | A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies | completed | Phase 1 | 17 | Handok Inc.INDUSTRY | 1 | Sep 16, 2021 | clinicaltrials |
| NCT04061863 | Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer(KORNELIA) | unknown | Phase 1 / Phase 2 | 90 | Seoul National University HospitalOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT02471716 | Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor(FPA008-002) | completed | Phase 1 / Phase 2 | 66 | Five Prime Therapeutics, Inc.INDUSTRY | 6 | Aug 31, 2021 | clinicaltrials |
| NCT04526470 | Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer | unknown | Phase 1 / Phase 2 | 55 | Seoul National University Bundang HospitalOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT03898791 | A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer | completed | Phase 1 | 48 | Eli Lilly and CompanyINDUSTRY | 8 | Aug 5, 2021 | clinicaltrials |
| NCT01123876 | Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor | completed | Phase 1 | 60 | AbbVie (prior sponsor, Abbott)INDUSTRY | 2 | Aug 2, 2021 | clinicaltrials |
| NCT04889651 | A Study to Compare the Pharmacokinetics and Safety Between BR9004 and BR9004-1 in Healthy Male Volunteers | completed | Phase 1 | 40 | Boryung Pharmaceutical Co., LtdINDUSTRY | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04872634 | A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment(SNK_ASTER) | unknown | Phase 1 / Phase 2 | 24 | NKMAX Co., Ltd.INDUSTRY | 1 | Jul 21, 2021 | clinicaltrials |
| NCT02197247 | Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC | completed | Phase 1 | 41 | AstraZenecaINDUSTRY | 6 | Jul 12, 2021 | clinicaltrials |
| NCT02715531 | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | completed | Phase 1 | 243 | Hoffmann-La RocheINDUSTRY | 7 | Jul 9, 2021 | clinicaltrials |
| NCT03292783 | This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001 | completed | Phase 1 | 45 | ABL Bio, Inc.INDUSTRY | 1 | Jul 7, 2021 | clinicaltrials |
| NCT03695757 | Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG | completed | Phase 1 / Phase 2 | 24 | Ajou University School of MedicineOTHER | 1 | Jul 6, 2021 | clinicaltrials |
| NCT04943653 | Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal Metastasis(IPXELOX) | unknown | Phase 1 / Phase 2 | 61 | Seoul St. Mary's HospitalOTHER | 1 | Jul 6, 2021 | clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT01823835 | A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | terminated | Phase 1 / Phase 2 | 152 | Genentech, Inc.INDUSTRY | 4 | Jun 18, 2021 | clinicaltrials |
| NCT02349633 | Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) | terminated | Phase 1 / Phase 2 | 65 | PfizerINDUSTRY | 4 | Jun 10, 2021 | clinicaltrials |
| NCT02097810 | Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.(STARTRK-1) | completed | Phase 1 | 84 | Hoffmann-La RocheINDUSTRY | 2 | Jun 9, 2021 | clinicaltrials |
| NCT04913662 | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel in Gastric Cancer Patients With Peritoneal Metastasis | unknown | Phase 1 | 18 | Seoul National University Bundang HospitalOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT04888663 | Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study) | unknown | Phase 1 / Phase 2 | 50 | Yonsei UniversityOTHER | 1 | May 21, 2021 | clinicaltrials |
| NCT01199068 | CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 15 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | May 13, 2021 | clinicaltrials |
| NCT01693562 | A Phase 1/2 Study to Evaluate MEDI4736 | completed | Phase 1 / Phase 2 | 1,022 | MedImmune LLCINDUSTRY | 9 | May 13, 2021 | clinicaltrials |
| NCT02499224 | Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy | completed | Phase 1 | 39 | CellabMEDINDUSTRY | 1 | May 13, 2021 | clinicaltrials |
| NCT01976741 | Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib) | completed | Phase 1 | 168 | BayerINDUSTRY | 7 | May 6, 2021 | clinicaltrials |
| NCT03552406 | Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 33 | ISU Abxis Co., Ltd.INDUSTRY | 1 | May 6, 2021 | clinicaltrials |
| NCT04842370 | Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML | unknown | Phase 1 | 42 | Seoul National University HospitalOTHER | 1 | Apr 20, 2021 | clinicaltrials |
| NCT02901301 | Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer | unknown | Phase 1 / Phase 2 | 41 | Yonsei UniversityOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT01938612 | A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours | completed | Phase 1 | 269 | AstraZenecaINDUSTRY | 3 | Mar 12, 2021 | clinicaltrials |
| NCT01781403 | Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer | completed | Phase 1 | 22 | Asan Medical CenterOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT02572687 | A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | completed | Phase 1 | 85 | Eli Lilly and CompanyINDUSTRY | 8 | Jan 20, 2021 | clinicaltrials |
| NCT02992340 | Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC | terminated | Phase 1 / Phase 2 | 204 | ASLAN PharmaceuticalsOTHER | 3 | Jan 14, 2021 | clinicaltrials |
| NCT02228369 | Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer(BLOOM) | completed | Phase 1 | 108 | AstraZenecaINDUSTRY | 4 | Jan 5, 2021 | clinicaltrials |
| NCT01602315 | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 179 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 29, 2020 | clinicaltrials |
| NCT01324479 | Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors | completed | Phase 1 | 131 | Novartis PharmaceuticalsINDUSTRY | 15 | Dec 19, 2020 | clinicaltrials |
| NCT01402440 | Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma | terminated | Phase 1 | 15 | Novartis PharmaceuticalsINDUSTRY | 10 | Dec 19, 2020 | clinicaltrials |
| NCT01598077 | A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer | completed | Phase 1 | 54 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 19, 2020 | clinicaltrials |
| NCT01602406 | Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer | completed | Phase 1 | 64 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT01822613 | Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) | completed | Phase 1 | 48 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT01854606 | Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma(COEB071X2103) | completed | Phase 1 | 31 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT00670592 | Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | completed | Phase 1 / Phase 2 | 111 | Novartis PharmaceuticalsINDUSTRY | 11 | Dec 17, 2020 | clinicaltrials |
| NCT02088684 | Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer | completed | Phase 1 | 70 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 17, 2020 | clinicaltrials |
| NCT02292550 | Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer. | completed | Phase 1 | 27 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 17, 2020 | clinicaltrials |
| NCT04667975 | The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy(CKD-702) | unknown | Phase 1 | 74 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Dec 16, 2020 | clinicaltrials |
| NCT03081494 | Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer | completed | Phase 1 | 10 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 11, 2020 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials